...Korea to develop and commercialize undisclosed neurotoxin products from Medytox (see BioCentury Sept 30, 2013). Medytox Inc....

...grant Allergan exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...in milestones, plus royalties. Allergan declined to provide details, and Medytox could not be reached. Medytox Inc....

...Phase II testing to treat psoriasis. Top-line data are expected in 1Q14. South Korean biotech Medytox Inc....
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...upfront payment of $65 million and is eligible for $297 million in milestones, plus royalties. Medytox...

...South Korean biotech Medytox Inc. (KOSDAQ:086900) gained W17,000 (12%) to W155,000 on Thursday after it and Allergan...
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...is eligible for $297 million in milestones, plus royalties. Allergan declined to provide details and Medytox...